Moderna 2022 Priorities and Capital Allocation

Moderna's Latent & Public Health Vaccines (Pipeline 2/3) ID # Preclinical development Phase 1 Phase 2 Phase 3 Commercial Moderna rights mRNA-1647 Worldwide Modality Program CMV vaccine EBV vaccine (to prevent mRNA-1189 Latent infectious mononucleosis) vaccines EBV vaccine (to prevent EBV sequelae) mRNA-1195 HSV vaccine mRNA-1608 VZV vaccine mRNA-1468 mRNA-1644 HIV vaccines mRNA-1574 Zika vaccine mRNA-1893 Public health vaccines Nipah vaccine mRNA-1215 Open IND Slide 41 Worldwide Worldwide Worldwide Worldwide Worldwide IAVI/others funded Worldwide BMGF/NIAID/ others funded Worldwide BARDA funded Worldwide NIH funded moderna

View entire presentation